Harmony Biosciences
HRMY
147 hedge funds and large institutions have $1.9B invested in Harmony Biosciences in 2021 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 40 increasing their positions, 31 reducing their positions, and 14 closing their positions.
329% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 14
60% more capital invested
Capital invested by funds: $1.19B → $1.9B (+$714M)
44% more funds holding
Funds holding: 102 → 147 (+45)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
29% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 31
21.95% more ownership
Funds ownership: 54.26% → 76.21% (+22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$84.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$12.9M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NP
Newlight Partners
New York
|
-$39.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.6M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$12.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$10M |
| 5 |
ACM
Aisling Capital Management
New York
|
-$9.46M |
HRMY Hedge Fund Activity: Q4 2021 in Review
147 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2021, worth a combined $1.9B — up 60% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new HRMY positions and 14 closed out — a net gain of 46 holders — while 40 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $84.7M. The largest seller was Newlight Partners, cutting an estimated $39.9M.
- 147 institutional investors held Harmony Biosciences (HRMY) as of Q4 2021, up from 102 in Q3 2021.
- Funds reported $1.9B of Harmony Biosciences stock for Q4 2021, up 60% quarter-over-quarter.
- 60 funds opened new Harmony Biosciences positions in Q4 2021 and 14 closed out, a net change of +46 holders.
- The largest Harmony Biosciences buyer in Q4 2021 was BlackRock, an estimated $84.7M added.
- The largest Harmony Biosciences seller in Q4 2021 was Newlight Partners, an estimated $39.9M sold.
Based on aggregated 13F filings for Q4 2021.